Literature DB >> 3047022

Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis.

P G Cavanaugh1, B F Sloane, K V Honn.   

Abstract

The ability of tumor cells to initiate coagulation and subsequent platelet aggregation is believed to facilitate the metastatic process. The mechanism by which tumor cells initiate thrombotic alterations is unclear. We have purified a plasma membrane protein platelet aggregating activity/procoagulant activity (PAA/PCA) from several rodent tumors which initiates the coagulation of homologous plasma and aggregation of homologous platelets by a mechanism independent of factor VII. This protein does not possess any proteinase activity; however, its activity is dependent upon the presence of factor X. In addition, PAA/PCA requires reconstitution with phospholipid for expression of activity. These results suggest that tumor cells express a unique protein which possesses procoagulant activity resulting in thrombin generation. Thrombin is responsible for subsequent tumor-cell-induced platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047022     DOI: 10.1159/000215781

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  12 in total

1.  Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction?

Authors:  H Chopra; J Timar; X Rong; I M Grossi; J S Hatfield; S E Fligiel; C A Finch; J D Taylor; K V Honn
Journal:  Clin Exp Metastasis       Date:  1992-03       Impact factor: 5.150

2.  High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma.

Authors:  Jun Du; Jian-Hua Zheng; Xu-Sheng Chen; Qing Yang; Yan-Hui Zhang; Lei Zhou; Xin Yao
Journal:  Int J Clin Oncol       Date:  2012-05-19       Impact factor: 3.402

3.  Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo.

Authors:  M L Nierodzik; A Plotkin; F Kajumo; S Karpatkin
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

4.  Molecular imaging of fibrin in a breast cancer xenograft mouse model.

Authors:  Ritika Uppal; Zdravka Medarova; Christian T Farrar; Guangping Dai; Anna Moore; Peter Caravan
Journal:  Invest Radiol       Date:  2012-10       Impact factor: 6.016

5.  Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation.

Authors:  J Timar; H Chopra; X Rong; J S Hatfield; S E Fligiel; J M Onoda; J D Taylor; K V Honn
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  siRNA-mediated silencing of integrin β3 expression inhibits the metastatic potential of B16 melanoma cells.

Authors:  Anna Nasulewicz-Goldeman; Barbara Uszczyńska; Katarzyna Szczaurska-Nowak; Joanna Wietrzyk
Journal:  Oncol Rep       Date:  2012-08-10       Impact factor: 3.906

7.  High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance.

Authors:  Laura Caggiari; Massimo Guidoboni; Emanuela Vaccher; Luigi Barzan; Giovanni Franchin; Annunziata Gloghini; Debora Martorelli; Paola Zancai; Maria Teresa Bortolin; Mario Mazzucato; Diego Serraino; Antonino Carbone; Paolo De Paoli; Riccardo Dolcetti
Journal:  Infect Agent Cancer       Date:  2007-03-01       Impact factor: 2.965

8.  Revisiting perioperative chemotherapy: the critical importance of targeting residual cancer prior to wound healing.

Authors:  William W Harless
Journal:  BMC Cancer       Date:  2009-04-22       Impact factor: 4.430

9.  Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.

Authors:  H S Chiang; R S Yang; S W Lin; T F Huang
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

10.  Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostomin.

Authors:  H S Chiang; R S Yang; T F Huang
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.